Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Journal of Clinical Oncology, Journal Year: 2022, Volume and Issue: 40(25), P. 2924 - 2933

Published: May 16, 2022

Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non-small-cell lung cancer (NSCLC) the NADIM trial (ClinicalTrials.gov identifier: NCT03081689). The 3-year overall survival (OS) and circulating tumor DNA (ctDNA) analysis have not reported.This was an open-label, multicenter, single-arm, phase II which patients with stage IIIA NSCLC, who were deemed surgically resectable, treated neoadjuvant paclitaxel (200 mg/m2 once a day) carboplatin (area under curve 6) (360 mg) on day 1 of each 21-day cycle, for three cycles, followed by adjuvant monotherapy year (240 mg every 2 weeks 4 months, 480 8 months). OS ctDNA secondary objectives trial.OS at 36 months 81.9% (95% CI, 66.8 90.6) intention-to-treat population, rising 91.0% 74.2 97.0) per-protocol population. Neither mutation burden nor programmed cell death ligand-1 staining predictive survival. Conversely, low pretreatment levels significantly associated improved progression-free (hazard ratio [HR], 0.20; 95% 0.06 0.63, HR, 0.07; 0.01 0.39, respectively). Clinical responses according RECIST v1.1 criteria did predict outcomes. However, undetectable after treatment (HR, 0.26; 0.07 0.93, 0.04; 0.00 0.55, C-index (0.82) superior that (0.72).The efficacy NSCLC is supported OS. outperformed radiologic assessments prediction

Language: Английский

---

Identification of Parameters Representative of Immune Dysfunction in Patients with Severe and Fatal COVID-19 Infection: a Systematic Review and Meta-analysis

Clinical Reviews in Allergy & Immunology, Journal Year: 2022, Volume and Issue: 64(1), P. 33 - 65

Published: Jan. 18, 2022

Language: Английский

---

Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in patients with lung cancer

ESMO Real World Data and Digital Oncology, Journal Year: 2025, Volume and Issue: 8, P. 100125 - 100125

Published: March 14, 2025

Language: Английский

---

Development and application of a UHPLC-MS/MS method for the simultaneous determination of firmonertinib and its main metabolite AST-5902 in rat plasma: a study on the in vivo drug interaction between firmonertinib and paxlovid

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: May 12, 2025

Due to the potential occurrence of drug interactions, combined application firmonertinib and paxlovid carries a relatively high risk. Nevertheless, as now, there has been no comprehensive research on interaction between paxlovid. Our aim was establish validate an accurate, stable, rapid simple UPLC-MS/MS method for simultaneous determination its metabolite AST-5902 in rat plasma, which applied study vivo Gefitinib selected internal standard. After protein precipitation plasma samples with acetonitrile, separation carried out Shimadzu LC-20AT UHPLC. The chromatographic column Shim-pack Volex PFPP (50 mm × 2.1 mm, 1.8 μm), mobile phase composed 0.1% formic acid - water methanol. Mass spectrometry detection performed using 8,040 mass spectrometer ESI+ MRM mode. precision, accuracy, recovery matrix effect this were detected. linearity stability assessed. Subsequently, parent ions typical fragment firmonertinib, IS are respectively m/z 569.25 → 72.15, 555.50 498.10 447.25→ 128.20. selectivity, specificity, linearity, recovery, effect, accuracy precision all adequately verified. results showed that when paxlovid, AUC Cmax significantly increased, while AUC, Tmax, decreased. established UHPLC-MS/MS is simple. Paxlovid exhibit significant inhibitory metabolism rats.

Language: Английский

---

A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

Journal of Thoracic Oncology, Journal Year: 2022, Volume and Issue: 17(5), P. 661 - 674

Published: Feb. 1, 2022

Language: Английский

---

Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic

Cancers, Journal Year: 2022, Volume and Issue: 14(15), P. 3598 - 3598

Published: July 23, 2022

Cancer patients, specifically lung cancer show heightened vulnerability to severe COVID-19 outcomes. The immunological and inflammatory pathophysiological similarities between COVID-19-related ARDS might explain the predisposition of patients COVID-19, while multiple risk factors in have been associated with worse outcomes, including smoking status, older age, etc. Recent treatments also urgently evaluated during pandemic as potential for conflicting findings regarding systemic chemotherapy radiation therapy, other therapies were not altered Given this delivery care was significantly modified both proceed minimize SARS-CoV-2 infection risk. However, delays patients' aversion clinical settings led increased diagnosis more advanced tumors, an expected increase mortality. Waning immunity vaccine breakthroughs related novel variants concern threaten further impede services. a high despite being fully vaccinated. Numerous early developed prevent disease progression are crucial infected outcomes resume care. In literature review, we will explore lessons learned mitigate treatment decisions management patients.

Language: Английский

---

Effect of COVID-19 on Thoracic Oncology Surgery in Spain: A Spanish Thoracic Surgery Society (SECT) Survey

Cancers, Journal Year: 2021, Volume and Issue: 13(12), P. 2897 - 2897

Published: June 9, 2021

After the first wave of COVID-19, Spanish Society Thoracic Surgeons (SECT) surveyed its members to assess impact pandemic on thoracic oncology surgery in Spain. In May 2020, all SECT were invited complete an online, 40-item, multiple choice questionnaire. The questionnaire was developed by Scientific Committee and sent via email. overall response rate 19.2%. respondents answered at least 91.5% items, with only one exception (a question about residents). Most (89.3%) worked public hospitals. reported routine clinical activity considered extreme or severe 75.5% (25.5% 50%, respectively). Multidisciplinary tumour boards held either fewer attending through electronic platforms (44.6% 35.9%, Surgical decreased 95.7%, 41.5% centers performing oncological patients 11.7% emergencies. Nearly 60% modifying standard protocols for early-stage cancer preoperative workup. (≈80%) using full personal protective equipment when operating COVID-19 positive patients. severely affected lack common led a variable care delivery lung

Language: Английский

---

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

BMC Cancer, Journal Year: 2022, Volume and Issue: 22(1)

Published: July 5, 2022

Abstract Background The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and emergence immunotherapy itself. work aims study situation biomarker testing Spain. Patients methods Thoracic Tumours Registry (TTR) is an observational, prospective, registry-based that included diagnosed other thoracic tumours, from September 2016 2020. TTR was sponsored Spanish Lung Cancer Group (GECP) Foundation, independent, scientific, multidisciplinary oncology society coordinates more than 550 experts 182 hospitals across territory. Results Nine thousand two hundred thirty-nine stage IV non-small cell (NSCLC) between 2106 2020 were analysed. 7,467 (80.8%) non-squamous 1,772 (19.2%) squamous. Tumour marker performed 85.0% tumours vs 56.3% those squamous ( p -value < 0.001). global EGFR, ALK, ROS1 78.9, 64.7, 35.6% respectively, histology. PDL1 determined globally same period (46.9%), although if we focus on 3 years it exceeds 85%. There been a significant few all determinations there are even close 10% molecular do not yet have drug approval but will near future. 4,115 cases had positive result (44.5%) either KRAS, BRAF, ROS1, or high PDL1. Conclusions Despite lack national project standard protocol Spain regulates determination biomarkers, similar European countries. Given growing number different their positivity, strategies urgently needed implement next-generation sequencing (NGS) integrated cost-effective way cancer.

Language: Английский

---

Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis

Clinical Lung Cancer, Journal Year: 2024, Volume and Issue: 25(5), P. e229 - e237.e7

Published: April 10, 2024

Language: Английский

---

Clinical Characteristics, Care Trajectories and Mortality Rate of SARS-CoV-2 Infected Cancer Patients: A Multicenter Cohort Study

Cancers, Journal Year: 2021, Volume and Issue: 13(19), P. 4749 - 4749

Published: Sept. 23, 2021

COVID-19 may be more frequent and severe in cancer patients than other individuals. Our aims were to assess the rate of hospitalized patients, describe their demographic characteristics, clinical features care trajectories, mortality rate.This multicenter cohort study was based on Electronic Health Records Assistance Publique-Hôpitaux de Paris (AP-HP). Cancer with a diagnosis between 3 March 19 May 2020 included. Main outcome all-cause within 30 days diagnosis.A total 29,141 identified 7791 (27%) tested for SARS-CoV-2. Of these, 1359 (17%) COVID-19-positive 1148 (84%) hospitalized; 217 (19%) admitted an intensive unit. The 33% (383 deaths). In multivariate analysis, mortality-related factors male sex (aHR = 1.39 [95% CI: 1.07-1.81]), advanced age (78-86 y: aHR 2.83 1.78-4.51] vs. <66 y; 86-103 2.61 1.56-4.35] y), two comorbidities 2.32 1.41-3.83]) C-reactive protein >20 ng/mL 2.20 1.70-2.86]). Primary brains tumors 2.19 1.08-4.44]) lung 1.66 1.02-2.70]) associated higher mortality. Risk dying lower among metabolic 0.65 0.50-0.84]).In hospital-based setting, had high rate. This mainly driven by age, sex, number presence inflammation. is first which better outcome.

Language: Английский

---